LGE and the Risk of Sudden Death in HCM
We read with interest the recent paper by Green et al. (1) and wish to congratulate them for this timely article. The investigators performed a meta-analysis assessing the value of late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) for predicting clinical outcomes in hypertrophic cardiomyopathy. Although the investigators found a significant association between LGE and cardiac death, heart failure death, and all-cause mortality, this was not statistically significant for sudden cardiac death (SCD) or aborted SCD. In this regard, we would like to point to 3 important issues. First, in the study by O'Hanlon et al. (2) , the authors report SCD/aborted SCD events as 3 and 1 in the LGEϩ and LGEϪ groups, respectively. However, if one were to review this paper carefully, O'Hanlon et al. (2) report sustained ventricular tachycardia (VT)/ventricular fibrillation (VF), SCD, and appropriate implantable cardioverter-defibrillator (ICD) discharges separately. The composite arrhythmic event rates were in fact 10 and 2 in the LGEϩ and LGEϪ groups, respectively. We believe that sustained VT or VF should be construed as clinically significant endpoints and be grouped with SCD/aborted SCD. If one were to repeat the analysis using these numbers, LGE on CMR would be significantly associated with SCD/aborted SCD with an odds ratio of 2.75 (95% confidence interval: 1.10 to 6.84; p ϭ 0.02) as shown in Figure 1 . Second, despite not finding significant heterogeneity, the authors should have tested the robustness of their analysis by using alternative weighting methods and random effects model. Statistical tests for heterogeneity are known to have low power when the number of studies is small and weighting methods are impacted by low/zero event rates, as is the case with the current study (3) . In our analysis using the above proposed event rates for the O'Hanlon study (2) , there was no change in the directionality or magnitude of the result whether we used random effects model or fixed effects model with Mantel-Haenszel weighting or Peto method of weighting. The odds ratios were 2.75, 3.37, and 2.76, respectively with all p values being statistically significant at Ͻ0.05. The consistency of the findings, therefore, add strength to our conclusion that LGE on CMR predicts clinically significant ventricular arrhythmias (SCD/aborted, SCD/sustained, VT/VF).
Third, though the authors highlight the limitations of the current techniques of LGE ascertainment, and emphasize the need for more quantitative assessment of LGE, the issue of disparate LGE cutoffs warrants further discussion. While Maron et al. (4) used a threshold signal intensity of Ն6 standard deviations (SD) above mean to define LGE, Bruder et al. (5) used a cutoff of 2 SD, and O'Hanlon et al. (2) used the "full width half maximum" method, highlighting the wide variability in current methods. To add to the uncertainty about the cutoffs for defining LGE in patients with hypertrophic cardiomyopathy, a recent report by Appelbaum et al. (6) 
Figure 1. Forest Plot and Pooled Odds Ratio for Sudden Death/Aborted Sudden Death
Forest plot and pooled odds ratio for sudden death/aborted sudden death with late gadolinum enhancement using revised event rates in the O'Hanlon study (2) . CI ϭ confidence interval.
LGE (Ն4 but Ͻ6 SD) is a better predictor of ventricular tachyarrhythmias than high signal intensity LGE (Ͼ6 SD). In conclusion, as Green et al. (1) appropriately point out, the more important question is not whether LGE predicts SCD, but rather does it add incremental information above and beyond that provided by the conventional and less expensive models based on clinical and echocardiographic factors. Would we be able to identify patients with 2 or more conventional risk factors that would not need ICD based on CMR and would we be able to correctly predict the need for ICD in a subset of patients with no conventional risk factors?
We thank Dr. Alla and colleagues for their insightful comments. While we agree that sustained ventricular tachycardia (VT)/ ventricular fibrillation (VF) is an important arrhythmic endpoint, and is certainly a marker for increased risk of sudden cardiac death (SCD), our goal was specifically to evaluate hard endpoint of SCD and aborted SCD. As 3 of 4 included studies did not uniformly report on the incidence of sustained/nonsustained VT/VF, true prevalence of these events could not be adequately assessed from these studies. Furthermore, additional studies which do not assess SCD have demonstrated an association between cardiac magnetic resonance (CMR) and VT and would need to be included for an adequate analysis. As proposed, a future multicenter study would enable more uniform assessment of these arrhythmic events and other endpoints in the context of traditional risk markers, genetics, and other CMR markers without the statistical limitations inherent in the current limited data. Given the assessment of heterogeneity, a fixed effects model was statistically justifiable; however, the point made by Alla et al. regarding the assessment of heterogeneity with a small number of studies is well taken. The pooled raw data was reanalyzed assuming a random effects model with very similar results ( Table 1) . Only cardiovascular death failed to reach statistical significance (p ϭ 0.1) with a random effects model. This discrepancy is likely driven by the low numbers and the discordant results of the Maron study (1), which had a younger population as compared with the other 3 studies (2-4) . Alla et al. raise an interesting point with regard to the current methods for quantifying left gadolinium enhancement (LGE) on the basis of a fixed standard deviation of signal intensity relative to the remote myocardium, which is dependent upon a number of confounding factors including the signal-to-noise ratio of the images, gadolinium dose, timing of imaging after contrast administration, noise statistics, and the assumption that the remote myocardium is "normal," which is now suspect given evidence for diffusely abnormal T1 values (indicating diffuse fibrosis) even in the absence of focal fibrosis. This more diffuse fibrosis may also be a risk for arrhythmic events. Further standardization in the definition of abnormal LGE in hypertrophic cardiomyopathy would enable us to determine if cutoffs based upon SD are truly predictive.
The question about whether LGE adds incremental information to conventional risk factors cannot be answered with the currently available data. The studies performed to date possess an older population of whom the vast majority have Ͻ2 traditional risk factors for SCD (as their eligibility for CMR in these studies signified that they had not already received implantable cardioverter-defibrillator [ICD] placement for primary prevention as indicated for those with Ն2 traditional risk factors). Alla et al. propose 2 distinct clinical scenarios in which thoughtful clinical evaluation by the cardiologist is vital: no scar by CMR with Ն2 traditional risk factors versus scar by CMR with Ͻ2 traditional risk factors. In the first scenario, one must acknowledge the risks associated with ICD placement and recognize the effects of both Values are odds ratio (95% confidence interval). HF ϭ heart failure; SCD ϭ sudden cardiac death.
